New IBS indication for Kolanticon

The licenced indication for Kolanticon Gel has been extended to include the symptomatic control of medically-confirmed irritable bowel syndrome (IBS).

First indicated as an antacid medicine over 30 years ago, Kolanticon Gel has been used for the treatment of stomach complaints, helping to relieve painful cramps, indigestion and flatulence. 

Kolanticon Gel has four active ingredients suitable for IBS relief. Each 5ml spoonful of the medicine contains 2.5mg dicycloverine hydrochloride, a smooth muscle antispasmodic, 200mg aluminium hydroxide and 100mg light magnesium hydroxide, both antacid compounds for treating dyspepsia, and 20mg simethicone, an ‘anti foaming agent’ and well known antiflatulent.

Collectively these ingredients offer a multi-symptom relief approach to abdominal pain, cramping, dyspepsia and bloating, all recognised features of the IBS condition. 

Available in liquid form in 200ml and 500ml bottles, the recommended dose of Kolanticon Gel for adults and children over 12 years old is two to four 5ml spoonfuls every four hours as required. 


Notes to Editors:

Peckforton Pharmaceuticals, based in Crewe, specialises in the sourcing, licensing and supply of generic pharmaceuticals for the hospital market in the UK.  In addition to its Pharmacy product, Kolanticon Gel, it offers a range of other antacid products. 

For further information contact: 

Andrew Crosbie, Director, Harris Moore Public Relations, Tel : 0794 799 2022

E :


Gregory Whelan, Sales & Marketing Director,  Peckforton Pharmaceuticals Ltd,

Tel : 01270 582255   E :

Healthcare Republic does not have an editorial influence or input in to these press releases. The views expressed within these documents are not endorsed by Healthcare Republic or Haymarket Medical Publications Limited.

Enquiries should be directed to any contacts listed within the press releases.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in